Stomach cancer hope: new combo targets tumors after PD-1 failure

NCT ID NCT06417892

Recruiting now Disease control Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 29, 2026 · Updated 3 times

Summary

This study tests a combination of fruquintinib (a drug that blocks blood vessel growth to tumors) and chemotherapy (albumin-paclitaxel), with or without a PD-1 antibody, for people with advanced stomach or gastroesophageal junction cancer whose first PD-1 treatment stopped working. The goal is to see if adding the PD-1 antibody again improves how long the cancer stays under control. About 60 adults will take part, and the study tracks side effects and survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: fruquintinib, albumin-paclitaxel (chemotherapy), and a PD-1 antibody
What this could lead to: If successful, this could offer a new second-line treatment option for advanced gastric cancer patients whose first PD-1 therapy stopped working.
What could go wrong: This is a small, early-phase study (60 people) in China, so results may not apply broadly. The combination adds more drugs, which could increase side effects without improving outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED GASTRIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastric cancer gastric neoplasm gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTRIC CANCER

Contacts and locations

Locations

Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
RECRUITING

Beijing, Beijing Municipality, 100021, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.